Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Performance

EVGN stock opened at $1.31 on Wednesday. Evogene has a 52 week low of $1.20 and a 52 week high of $9.00. The company’s 50-day simple moving average is $1.48 and its 200 day simple moving average is $1.85. The company has a market capitalization of $7.03 million, a PE ratio of -0.29 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter in the prior year, the business posted ($1.30) EPS.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.